Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Safety of combination of ibrutinib and radiation at various dose levels in unmethylated
o6-methylguanine-DNA-methyltransferase (MGMT) glioblastoma and study of ibrutinib,
temozolomide, and radiation combination therapy in methylated MGMT glioblastoma.